Using cerebrospinal fluid from living patients, researchers have identified specific proteins and genetic pathways involved in the development and progression of Alzheimer’s disease.

EMA committee recommends approval of Eisai & Biogen’s lecanemab to treat early Alzheimer’s disease: Tokyo Saturday, November 16, 2024, 13:00 Hrs [IST] Eisai Co., Ltd. and Biog ...

and are at increased risk of developing Alzheimer’s disease. Those with one copy are at increased risk too. Leqembi, which is ...

Lecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of ...

A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan targeting proteins in the brains of sufferers of the debilitating disease, will cost 3.08 ...